PMID- 37806104
OWN - NLM
STAT- MEDLINE
DCOM- 20231101
LR  - 20231101
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 124
IP  - Pt B
DP  - 2023 Nov
TI  - Effect of mesenchymal stem cell therapy in animal models of allergic rhinitis: A 
      systematic review and meta-analysis.
PG  - 111003
LID - S1567-5769(23)01328-0 [pii]
LID - 10.1016/j.intimp.2023.111003 [doi]
AB  - BACKGROUND: Allergic rhinitis (AR) is a worldwide problem that affects people of 
      all ages, impairing patients' physical and mental health and causing great social 
      expenditure. Animal studies have suggested the potential efficacy of mesenchymal 
      stem cell (MSC) therapy in treating AR. Our meta-analysis was performed to 
      evaluate the effect of MSC therapy in animal models of AR by pooling animal 
      studies. METHODS: The search was executed in PubMed, Embase, Web of Science, 
      OVID, and the Cochrane Library for relevant studies up to February 2023. The 
      applicable data were extracted from the eligible studies, and the risk of bias 
      was assessed for each study. The meta-analysis was conducted using Review Manager 
      (version 5.4.1) and Stata (version 15.1). RESULTS: A total of 12 studies were 
      included in the final analysis. Compared to the model control group, the MSC 
      therapy group presented lower frequency of sneezing [(Standardized mean 
      difference (SMD) -1.87, 95% CI -2.30 to -1.43)], nasal scratching (SMD -1.41, 95% 
      CI -1.83 to -0.99), and overall nasal symptoms (SMD -1.88, 95% CI -3.22 to 
      -0.54). There were also remarkable reductions after transplantation with MSCs in 
      the levels of total immunoglobulin E (IgE) (SMD -1.25, 95% CI -1.72 to -0.79), 
      allergen-specific IgE (SMD -1.79, 95% CI -2.25 to -1.32), and allergen-specific 
      immunoglobulin G1 (SMD -1.29, 95% CI -2.03) in serum, as well as the count of 
      eosinophils (EOS) in nasal mucosa (SMD -3.48, 95% CI -4.48 to -2.49). In terms of 
      cytokines, MSC therapy significantly decreased both protein and mRNA levels of T 
      helper cell 2 (Th2)-related cytokines, including interleukin (IL)-4, IL-5, IL-10, 
      and IL-13. CONCLUSION: MSC therapy has the potential to be an effective clinical 
      treatment for AR patients by attenuating Th2 immune responses, reducing secretion 
      of IgE and nasal infiltration of EOS, and consequently alleviating nasal 
      symptoms.
CI  - Copyright (c) 2023 The Author(s). Published by Elsevier B.V. All rights reserved.
FAU - Hong, Dongdong
AU  - Hong D
AD  - Department of Otorhinolaryngology, Shenzhen Traditional Chinese Medicine 
      Hospital, Shenzhen 518033, China.
FAU - Hu, Zhen
AU  - Hu Z
AD  - Department of Otorhinolaryngology, Shenzhen Traditional Chinese Medicine 
      Hospital, Shenzhen 518033, China.
FAU - Weng, Juanling
AU  - Weng J
AD  - Department of Otorhinolaryngology, Shenzhen Traditional Chinese Medicine 
      Hospital, Shenzhen 518033, China.
FAU - Yang, Long
AU  - Yang L
AD  - Department of Otorhinolaryngology, Shenzhen Traditional Chinese Medicine 
      Hospital, Shenzhen 518033, China.
FAU - Xiong, Yalan
AU  - Xiong Y
AD  - Department of Otorhinolaryngology, Shenzhen Traditional Chinese Medicine 
      Hospital, Shenzhen 518033, China.
FAU - Liu, Yuanxian
AU  - Liu Y
AD  - Department of Otorhinolaryngology, Shenzhen Traditional Chinese Medicine 
      Hospital, Shenzhen 518033, China. Electronic address: yxl_sztcm@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20231006
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Cytokines)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 0 (Allergens)
SB  - IM
MH  - Animals
MH  - Humans
MH  - *Mesenchymal Stem Cell Transplantation
MH  - *Rhinitis, Allergic/drug therapy
MH  - Nasal Mucosa
MH  - Cytokines/metabolism
MH  - Disease Models, Animal
MH  - Immunoglobulin E/metabolism
MH  - Allergens/pharmacology
MH  - *Mesenchymal Stem Cells/metabolism
OTO - NOTNLM
OT  - Allergic rhinitis
OT  - Animal study
OT  - Mesenchymal stem cells
OT  - Meta-analysis
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/10/09 00:41
MHDA- 2023/11/01 12:44
CRDT- 2023/10/08 18:13
PHST- 2023/03/09 00:00 [received]
PHST- 2023/09/06 00:00 [revised]
PHST- 2023/09/25 00:00 [accepted]
PHST- 2023/11/01 12:44 [medline]
PHST- 2023/10/09 00:41 [pubmed]
PHST- 2023/10/08 18:13 [entrez]
AID - S1567-5769(23)01328-0 [pii]
AID - 10.1016/j.intimp.2023.111003 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2023 Nov;124(Pt B):111003. doi: 
      10.1016/j.intimp.2023.111003. Epub 2023 Oct 6.